Shareprice
14 Jun 2024

Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

FluoGuide A/S issue warrants to employees and management

Press release


March 29, 2022

Copenhagen, Denmark, 29 March 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that based on the approved Incentive program from 9 February 2021, FluoGuide is issuing 40,000 warrants to management, and employees.

Today, the Board of Directors of FluoGuide has exercised its authorization to issue new warrants by issuing 40,000 warrants to employees and management. All warrants are issued free of change.

Warrants are issued to ensure alignment of interests between the Company’s employees, management, and shareholders. The Company believes that the issue of warrants will strengthen the achievement of FluoGuide’s short-term and long-term goals to support the Company’s business strategy, sustainability, and value creation for the benefit of shareholders.

The warrants are issued in accordance with FluoGuide’s authorization in Clause 3.1.4 of the Articles of Association.

Each warrant grants the holder the right to subscribe for (1) one new share in FluoGuide. The exercise price is fixed at SEK 65,00 per share. The warrants issued vest with 1/36 per month.

Todays issued warrants represents a total dilution of 0,3 % of the current share capital, if vested and exercised. The warrant program is the second warrant program to FluoGuide employees, management, and Board of Directors. The first warrant program was issued in May 2021.

Vested warrants may be exercised in two annual exercise periods of two weeks following publication of respectively the Annual Report and the Interim half-year report.

The detailed terms of all warrants issued by the Company can be found in the Articles of Association on the Company’s website under https://fluoguide.com/investor/compliance/, following registration with the Danish Business Authorities.

For further information, please contact:
Henrik Moltke, CFO
FluoGuide A/S
Phone: +45 22 44 54 04
E-mail: hm@fluoguide.com

Certified Adviser:

Svensk Kapitalmarknadsgransking AB
Phone: +46 70 755 95 51
E-mail: ca@skmg.se

About FluoGuide
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is has demonstrated early evidence of efficacy of F001 as well as it to be well tolerated and safe in the ongoing proof-of-concept clinical study (phase I/II) in patients with high grade glioma undergoing surgery. FG001 is also in phase II trial for lung cancer. FluoGuide is listed on Nasdaq First North Sweden under the ticker “FLUO”.